Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
Kelun-Biotech
#
Kelun-Biotech
About 5 search results
Sort by Date
Business
PR Newswire
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.
PR Newswire
2026-06-22 14:00
sacituzumab tirumotecan
sac-TMT
Osimertinib
Business
PR Newswire
Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378
CHENGDU, China
PR Newswire
2026-06-09 20:18
SKB378
WIN378
COPD
Business
PR Newswire
Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
CHENGDU, China
PR Newswire
2026-06-03 08:00
SKB500
Kelun-Biotech
B7-H3 ADC
Business
PR Newswire
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
CHENGDU, China
PR Newswire
2026-05-30 22:01
sacituzumab tirumotecan
sac-TMT
OptiTROP-Lung05
Business
PR Newswire
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
CHENGDU, China
PR Newswire
2026-05-30 21:51
Kelun-Biotech
lunbotinib fumarate
RET fusion-positive